Aptevo Therapeutics Inc. (APVO) SEC Filing 10-Q Quarterly report for the period ending Sunday, June 30, 2019

Aptevo Therapeutics Inc.

CIK: 1671584 Ticker: APVO

Exhibit 99.1


For Immediate Release





Reports Positive Preliminary Top-Line Safety Data for APVO210

Phase 1 Single Ascending Dose (SAD) Clinical Study


Advances APVO210 into Phase 1 Multiple Ascending Dose (MAD) Study


Commences Dosing in Cohort 4 of APVO436 Phase 1 AML/MDS Clinical Trial


Achieves 32% Increase in First Half 2019 Year-Over-Year IXINITY® Net Revenue;

Launches New 3,000 IU IXINITY Assay for Enhanced IXINITY User Experience & Convenience


Receives $4.3 Million Milestone Payment from Saol Therapeutics;

Reconfirms $36-$40 Million 2019 Cash Burn Guidance



SEATTLE, WA – August 9, 2019

-- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today provided a business review and reported its financial results for the second quarter ended June 30, 2019.


“We expect 2019 will be an important year for Aptevo from a clinical safety data perspective,” said Marvin L. White, President and Chief Executive Officer.  “With both our APVO210 and APVO436 programs making important progress in the clinic this year, we anticipate robust news flow over the next several quarters.  Preliminary clinical trial updates began from both programs in July 2019 and will continue over the next several quarters.”  


“We recently announced the first segment of clinical data from our APVO210 program, which is a potential first-in-class autoimmune-focused bispecific antibody. Dosing was completed in 64 healthy volunteers in a single ascending dose Phase 1 study of APVO210.  Preliminary data showed that APVO210 appears to be safe and well-tolerated at single intravenous doses up to 320 mcg/kg – well above doses which have generated clinical effects with previous competitor IL-10 investigational therapeutics.  No adverse events of concern or dose-limiting toxicities were noted, and most importantly, no evidence of anti-drug antibodies (ADA) was observed, based on patient samples to date.  We are excited to begin the second phase of the study, evaluating multiple ascending doses of APVO210.  We anticipate results from this study will read out in the first quarter of 2020 and we will also provide an update on clinical results to date at the end of the year.”




The following information was filed by Aptevo Therapeutics Inc. (APVO) on Friday, August 9, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Aptevo Therapeutics Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aptevo Therapeutics Inc..


Assess how Aptevo Therapeutics Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aptevo Therapeutics Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools


Learn More
Bullish Bearish Neutral
Filter Sentiment:
Filter Category:
Filter Subcategory:
Inside Aptevo Therapeutics Inc.'s 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets (Unaudited)
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)
Condensed Consolidated Statements Of Cash Flows (Unaudited)
Condensed Consolidated Statements Of Changes In Stockholders' Equity (Unaudited)
Condensed Consolidated Statements Of Comprehensive Loss (Unaudited)
Condensed Consolidated Statements Of Operations (Unaudited)
Cash, Cash Equivalents And Restricted Cash - Additional Information (Details)
Cash, Cash Equivalents And Restricted Cash - Schedule Of Cash, Cash Equivalents And Long-Term Restricted Cash (Details)
Cash, Cash Equivalents, And Restricted Cash
Cash, Cash Equivalents, And Restricted Cash (Tables)
Collaboration Agreements
Collaboration Agreements - Additional Information (Details)
Debt - Additional Information (Details)
Equity (Tables)
Equity - Additional Information (Details)
Equity - Assumptions Used In Valuing The Stock Options Granted Under Black-Scholes Valuation Model (Details)
Equity - Summary Of Restricted Stock Activity (Details)
Equity - Summary Of Stock Option Activity (Details)
Equity - Summary Of Stock-Based Compensation Expense Includes Amortization Of Stock Options And Restricted Stock Units Granted (Details)
Fair Value Measurements
Fair Value Measurements - Additional Information (Details)
Inventories (Tables)
Inventories - Schedule Of Inventories (Details)
Leases (Tables)
Leases - Additional Information (Details)
Leases - Components Of Lease Expense (Details)
Leases - Summary Of Future Minimum Lease Payments (Details)
Leases - Summary Of Right Of Use Assets Acquired Under Operating Leases (Details)
Nature Of Business And Significant Accounting Policies
Nature Of Business And Significant Accounting Policies (Policies)
Nature Of Business And Significant Accounting Policies - Additional Information (Details)
Net Loss Per Share
Net Loss Per Share (Tables)
Net Loss Per Share - Summary Of Potentially Dilutive Shares Excluded From Calculation Of Net Loss Per Share (Details)
Revenue Reserves
Revenue Reserves (Tables)
Revenue Reserves - Summary Of Product Revenue Allowance And Reserve Categories (Details)
Subsequent Event
Subsequent Event - Additional Information (Details)
Ticker: APVO
CIK: 1671584
Form Type: 10-Q Quarterly Report
Accession Number: 0001564590-19-031118
Submitted to the SEC: Fri Aug 09 2019 8:26:22 AM EST
Accepted by the SEC: Fri Aug 09 2019
Period: Sunday, June 30, 2019
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: